TW202320775A - 含源自大還魂之生物鹼製劑 - Google Patents
含源自大還魂之生物鹼製劑 Download PDFInfo
- Publication number
- TW202320775A TW202320775A TW111129633A TW111129633A TW202320775A TW 202320775 A TW202320775 A TW 202320775A TW 111129633 A TW111129633 A TW 111129633A TW 111129633 A TW111129633 A TW 111129633A TW 202320775 A TW202320775 A TW 202320775A
- Authority
- TW
- Taiwan
- Prior art keywords
- great
- resurrection
- derived
- preparation
- results
- Prior art date
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 67
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 31
- 241001643405 Stephania cephalantha Species 0.000 title abstract description 5
- 208000015181 infectious disease Diseases 0.000 claims abstract description 36
- DFOCUWZXJBAUSQ-URLMMPGGSA-N Berbamine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN(C)[C@@H](C=34)CC=3C=C(C(=CC=3)O)O3)=CC=21)OC)C1=CC=C3C=C1 DFOCUWZXJBAUSQ-URLMMPGGSA-N 0.000 claims abstract description 25
- DFOCUWZXJBAUSQ-UHFFFAOYSA-N Berbamine Natural products O1C(C(=CC=2)O)=CC=2CC(C=23)N(C)CCC3=CC(OC)=C(OC)C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 DFOCUWZXJBAUSQ-UHFFFAOYSA-N 0.000 claims abstract description 25
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 8
- WTXHFWYAETTXNF-XZWHSSHBSA-N (+)-Isotetrandrine Natural products O(C)c1c(OC)cc2c3[C@H](N(C)CC2)Cc2cc(c(OC)cc2)Oc2cc(ccc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13 WTXHFWYAETTXNF-XZWHSSHBSA-N 0.000 claims abstract description 4
- ANOXEUSGZWSCQL-LOYHVIPDSA-N Cycleanine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3N(C)CCC=4C=C(OC)C(OC)=C(C3=4)O3)C=21)OC)OC)C1=CC=C3C=C1 ANOXEUSGZWSCQL-LOYHVIPDSA-N 0.000 claims abstract description 4
- PEVPVMCJEMVCAS-UHFFFAOYSA-N Cycleanine Natural products COc1cc2CCN(C)C3Cc4ccc(Oc5cccc6CCN(C)C(Cc7ccc(Oc(c1OC)c23)cc7)c56)cc4 PEVPVMCJEMVCAS-UHFFFAOYSA-N 0.000 claims abstract description 4
- ANOXEUSGZWSCQL-UHFFFAOYSA-N O-Methyl-isochondodendrin Natural products O1C(C2=3)=C(OC)C(OC)=CC=3CCN(C)C2CC(C=C2)=CC=C2OC(C=23)=C(OC)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 ANOXEUSGZWSCQL-UHFFFAOYSA-N 0.000 claims abstract description 4
- WVTKBKWTSCPRNU-XZWHSSHBSA-N isotetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-XZWHSSHBSA-N 0.000 claims abstract description 4
- 241000711573 Coronaviridae Species 0.000 claims description 33
- 206010035664 Pneumonia Diseases 0.000 claims description 26
- 230000002458 infectious effect Effects 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 22
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 abstract description 13
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 abstract description 13
- 241001678559 COVID-19 virus Species 0.000 abstract description 7
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 4
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 27
- 230000000840 anti-viral effect Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 7
- -1 tertenine Chemical compound 0.000 description 7
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 4
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 4
- 208000001528 Coronaviridae Infections Diseases 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- YJRWQNIRFXVBRB-WDYNHAJCSA-N homoaromoline Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(O)C(OC)=CC3=C2[C@H]1N(C)CC3 YJRWQNIRFXVBRB-WDYNHAJCSA-N 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- QNQZPJLBGRQFDD-ZMSORURPSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N QNQZPJLBGRQFDD-ZMSORURPSA-N 0.000 description 2
- IDQUPXZJURZAGF-ZDUSSCGKSA-N (6as)-2,10,11-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-1-ol Chemical compound CN1CCC2=CC(OC)=C(O)C3=C2[C@@H]1CC1=CC=C(OC)C(OC)=C13 IDQUPXZJURZAGF-ZDUSSCGKSA-N 0.000 description 2
- MPYHGNAJOKCMAQ-MRXNPFEDSA-N (R)-laudanine Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H]1C2=CC(OC)=C(OC)C=C2CCN1C MPYHGNAJOKCMAQ-MRXNPFEDSA-N 0.000 description 2
- LVVKXRQZSRUVPY-HNNXBMFYSA-N (S)-coclaurine Chemical compound C([C@@H]1NCCC=2C=C(C(=CC=21)O)OC)C1=CC=C(O)C=C1 LVVKXRQZSRUVPY-HNNXBMFYSA-N 0.000 description 2
- BHLYRWXGMIUIHG-HNNXBMFYSA-N (S)-reticuline Chemical compound C1=C(O)C(OC)=CC=C1C[C@H]1C2=CC(O)=C(OC)C=C2CCN1C BHLYRWXGMIUIHG-HNNXBMFYSA-N 0.000 description 2
- BJWWOUUGCAPHOV-UHFFFAOYSA-N 1,3-dibenzylisoquinoline Chemical class C=1C2=CC=CC=C2C(CC=2C=CC=CC=2)=NC=1CC1=CC=CC=C1 BJWWOUUGCAPHOV-UHFFFAOYSA-N 0.000 description 2
- ZKIAZXMDELJIMQ-UHFFFAOYSA-N 2-norcepharanthine Natural products C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC(C2=C3)NCCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2C1N(C)CC3 ZKIAZXMDELJIMQ-UHFFFAOYSA-N 0.000 description 2
- SBGGUHPMRYOCBS-UHFFFAOYSA-N 9,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-1,2-diol Chemical compound CN1CCC2=CC(O)=C(O)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 SBGGUHPMRYOCBS-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- YJRWQNIRFXVBRB-UHFFFAOYSA-N Cycleapeltine Natural products C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC(C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(O)C(OC)=CC3=C2C1N(C)CC3 YJRWQNIRFXVBRB-UHFFFAOYSA-N 0.000 description 2
- 241001428935 Human coronavirus OC43 Species 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- FBCXFKWMGIWMJQ-IHLOFXLRSA-N Obaberine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OC)C(OC)=CC3=C2[C@H]1N(C)CC3 FBCXFKWMGIWMJQ-IHLOFXLRSA-N 0.000 description 2
- XGEAUXVPBXUBKN-WUFINQPMSA-N Obamegine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C(OC3=C(OC)C=C4CCN(C)[C@H](C4=C3)CC3=CC=C(C=C3)O3)C=21)O)OC)C1=CC=C(O)C3=C1 XGEAUXVPBXUBKN-WUFINQPMSA-N 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZKIAZXMDELJIMQ-IZLXSDGUSA-N ac1l48xb Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)NCCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 ZKIAZXMDELJIMQ-IZLXSDGUSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- XLWYWPDYNLZUJS-VQTJNVASSA-N aknadinine Chemical compound C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C(OC)=C(OC)C(=O)C2 XLWYWPDYNLZUJS-VQTJNVASSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- IIQSJHUEZBTSAT-VMPREFPWSA-N fangchinoline Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(O)C1=C23 IIQSJHUEZBTSAT-VMPREFPWSA-N 0.000 description 2
- IIQSJHUEZBTSAT-UHFFFAOYSA-N fangchinoline Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(O)C1=C23 IIQSJHUEZBTSAT-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UEAPAHNNFSZHMW-UHFFFAOYSA-N stepahnine Natural products COC1=CC=CC(C2=C34)=C1CC3N(C)CCC4=CC1=C2OCO1 UEAPAHNNFSZHMW-UHFFFAOYSA-N 0.000 description 2
- UEAPAHNNFSZHMW-CQSZACIVSA-N stephanine Chemical compound CN([C@@H]1CC2=C(C3=C11)C=CC=C2OC)CCC1=CC1=C3OCO1 UEAPAHNNFSZHMW-CQSZACIVSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VMBPWANOQIHTJG-IZLXSDGUSA-N (+)-2-norberbamine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN[C@@H](C=34)CC=3C=C(C(=CC=3)O)O3)=CC=21)OC)C1=CC=C3C=C1 VMBPWANOQIHTJG-IZLXSDGUSA-N 0.000 description 1
- OGJKMZVUJJYWKO-CYBMUJFWSA-N (+)-Stepharine Natural products C([C@H]1NCCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 OGJKMZVUJJYWKO-CYBMUJFWSA-N 0.000 description 1
- VJMBRWIHQHCVNM-URLMMPGGSA-N (+)-Thalrugosine Natural products O(C)c1c(O)c2Oc3c(OC)cc4c([C@@H](N(C)CC4)Cc4cc(Oc5c(OC)cc(cc5)C[C@H]5N(C)CCc(c25)c1)ccc4)c3 VJMBRWIHQHCVNM-URLMMPGGSA-N 0.000 description 1
- RUPUUZZJJXCDHS-UHFFFAOYSA-N (+)-orientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(O)=C(OC)C=C3CCN2C)=C1 RUPUUZZJJXCDHS-UHFFFAOYSA-N 0.000 description 1
- SBGGUHPMRYOCBS-ZDUSSCGKSA-N (6as)-9,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-1,2-diol Chemical compound CN1CCC2=CC(O)=C(O)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC)=C1 SBGGUHPMRYOCBS-ZDUSSCGKSA-N 0.000 description 1
- BOKVLBSSPUTWLV-INIZCTEOSA-N (S)-N-methylcoclaurine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=CC=21)O)OC)C1=CC=C(O)C=C1 BOKVLBSSPUTWLV-INIZCTEOSA-N 0.000 description 1
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 description 1
- KFHJXSRNLWMSOO-UHFFFAOYSA-N 2-Norcepharanoline Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCNC3CC2=CC=C(O)C1=C2 KFHJXSRNLWMSOO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VMBPWANOQIHTJG-UHFFFAOYSA-N 2-norberbamine Natural products O1C(C(=CC=2)O)=CC=2CC(C=23)NCCC3=CC(OC)=C(OC)C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 VMBPWANOQIHTJG-UHFFFAOYSA-N 0.000 description 1
- BIQLCSCFEQRHME-UHFFFAOYSA-N 2-norisotetrandrine Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2NCCC3=CC(OC)=C(OC)C1=C23 BIQLCSCFEQRHME-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- LFFQVHXIFJLJSP-IZLXSDGUSA-N 6,6'-dimethoxy-2,2'-dimethyl-oxyacanthan-7 Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=C(OC)C=C4CCN(C)[C@@H](C4=C3)CC=3C=C(C(=CC=3)O)O3)C=21)O)OC)C1=CC=C3C=C1 LFFQVHXIFJLJSP-IZLXSDGUSA-N 0.000 description 1
- CLWJGNIITFMBQR-UHFFFAOYSA-N Akuadilactam Natural products C1CC2=CC=C(OC)C(O)=C2C2(CC(=O)N3C)C13C(OC)=C(OC)C(=O)C2 CLWJGNIITFMBQR-UHFFFAOYSA-N 0.000 description 1
- LFFQVHXIFJLJSP-WUFINQPMSA-N Aromoline Natural products C([C@H]1N(C)CCC=2C=C(C(=C(OC3=C(OC)C=C4CCN(C)[C@H](C4=C3)CC=3C=C(C(=CC=3)O)O3)C=21)O)OC)C1=CC=C3C=C1 LFFQVHXIFJLJSP-WUFINQPMSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- LFFQVHXIFJLJSP-UHFFFAOYSA-N Candicusine Natural products O1C(C(=CC=2)O)=CC=2CC(C2=C3)N(C)CCC2=CC(OC)=C3OC(C=23)=C(O)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 LFFQVHXIFJLJSP-UHFFFAOYSA-N 0.000 description 1
- BOKVLBSSPUTWLV-UHFFFAOYSA-N D-N-Methyl coclaurine Natural products C1=2C=C(O)C(OC)=CC=2CCN(C)C1CC1=CC=C(O)C=C1 BOKVLBSSPUTWLV-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- XLWYWPDYNLZUJS-UHFFFAOYSA-N Hernandoline Natural products C1CC2=CC=C(OC)C(O)=C2C2(CCN3C)C13C(OC)=C(OC)C(=O)C2 XLWYWPDYNLZUJS-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QELDJEKNFOQJOY-ZDUSSCGKSA-N Isocorydine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=CC=C(OC)C(O)=C13 QELDJEKNFOQJOY-ZDUSSCGKSA-N 0.000 description 1
- YRYHFXJRUQQCBR-UHFFFAOYSA-N Isostephodelin Natural products C1C2=CC(OC)=C(OC)C=C2C23CC(=O)C(OC)=C(OC)C3C1N(C)CC2 YRYHFXJRUQQCBR-UHFFFAOYSA-N 0.000 description 1
- FBCXFKWMGIWMJQ-UHFFFAOYSA-N O-Methyllimacusine Natural products C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC(C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OC)C(OC)=CC3=C2C1N(C)CC3 FBCXFKWMGIWMJQ-UHFFFAOYSA-N 0.000 description 1
- KTAONUHTYCZKBS-UHFFFAOYSA-N O-methyl-isochondrodendrine Natural products O1C(C2=3)=C(OC)C(OC)=CC=3CCN(C)C2CC(C=C2)=CC=C2OC(C=23)=C(O)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 KTAONUHTYCZKBS-UHFFFAOYSA-N 0.000 description 1
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 description 1
- JYAPBWCAZXNDAR-UHFFFAOYSA-N Oxyacanthine Natural products COc1cc2CCN(C)C3Cc4ccc(Oc5cccc(CC6N(C)CCc7cc(OC)c(OC)c(Oc(c1)c23)c67)c5)c(O)c4 JYAPBWCAZXNDAR-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000745988 Phyllostachys Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 1
- YRYHFXJRUQQCBR-HLLQZAQXSA-N Tannagine Natural products O(C)c1c(OC)cc2c(c1)[C@@]13[C@@H](C(OC)=C(OC)C(=O)C1)[C@@H](N(C)CC3)C2 YRYHFXJRUQQCBR-HLLQZAQXSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- OGJKMZVUJJYWKO-ZDUSSCGKSA-N ac1lh1t2 Chemical compound C([C@@H]1NCCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 OGJKMZVUJJYWKO-ZDUSSCGKSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- CLWJGNIITFMBQR-WOJBJXKFSA-N aknadilactam Chemical compound C1CC2=CC=C(OC)C(O)=C2[C@@]2(CC(=O)N3C)[C@]13C(OC)=C(OC)C(=O)C2 CLWJGNIITFMBQR-WOJBJXKFSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 229930014594 aporphine alkaloid Natural products 0.000 description 1
- 150000008441 aporphines Chemical class 0.000 description 1
- 229930015408 benzyl-isoquinoline alkaloid Natural products 0.000 description 1
- 150000005516 benzylisoquinolines Chemical class 0.000 description 1
- WGAYWVXZSTXSBK-UHFFFAOYSA-N cephamonine Natural products C1C2=CC=C(OC)C(O)=C2C23CC(=O)C(OC)=C(OC)C3C1N(C)CC2 WGAYWVXZSTXSBK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- JACMJXVTWVRIGH-UHFFFAOYSA-N corydine Natural products COc1c(O)cc2CCN(C)C3Cc4cccc(C)c4c1c23 JACMJXVTWVRIGH-UHFFFAOYSA-N 0.000 description 1
- IDQUPXZJURZAGF-UHFFFAOYSA-N corydine hydrochloride Natural products CN1CCC2=CC(OC)=C(O)C3=C2C1CC1=CC=C(OC)C(OC)=C13 IDQUPXZJURZAGF-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- MPYHGNAJOKCMAQ-UHFFFAOYSA-N dl-Laudanidine Natural products C1=C(O)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1C MPYHGNAJOKCMAQ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- RKWPQIQYRNOTMT-CVEARBPZSA-N hasubanan Chemical class C1CC2=CC=CC=C2[C@@]23CCN[C@]21CCCC3 RKWPQIQYRNOTMT-CVEARBPZSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- DRVVGOFZCWCCSA-UHFFFAOYSA-N isocorydine Natural products COc1cc2CCN(C)C3Cc4cccc(C)c4c(c1O)c23 DRVVGOFZCWCCSA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930013053 morphinan alkaloid Natural products 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- HGNHIFJNOKGSKI-WDYNHAJCSA-N oxyacanthine Chemical compound C([C@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN(C)[C@H](C=34)CC3=CC=C(C=C3)O3)=CC=21)OC)C1=CC=C(O)C3=C1 HGNHIFJNOKGSKI-WDYNHAJCSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- OGJKMZVUJJYWKO-UHFFFAOYSA-N proaporphine Natural products C1=2C3=C(OC)C(OC)=CC=2CCNC1CC13C=CC(=O)C=C1 OGJKMZVUJJYWKO-UHFFFAOYSA-N 0.000 description 1
- HZRFPHXHCRIHFX-UHFFFAOYSA-N protosinomenine Natural products C1=C(O)C(OC)=CC=C1CC1C2=CC(OC)=C(O)C=C2CCN1C HZRFPHXHCRIHFX-UHFFFAOYSA-N 0.000 description 1
- UQNHXSCEVWBPSL-UHFFFAOYSA-N racemosinine A Natural products O1C(C(=CC=2)O)=CC=2CC(C2=C3)N(C)CCC2=CC(OC)=C3OC(C=23)=C(O)C(OC)=CC=2CCNC3CC2=CC=C1C=C2 UQNHXSCEVWBPSL-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BNUZUOWRDKPBQR-UHFFFAOYSA-N reticuline Natural products CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(O)=C1 BNUZUOWRDKPBQR-UHFFFAOYSA-N 0.000 description 1
- 102220081228 rs372168541 Human genes 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229930002966 sinomenine Natural products 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- VXPVPAHQYCJDTP-UHFFFAOYSA-N stephibaberine Natural products C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC(C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OC)C(O)=CC3=C2C1N(C)CC3 VXPVPAHQYCJDTP-UHFFFAOYSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021186784 | 2021-11-17 | ||
| JP2021-186784 | 2021-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202320775A true TW202320775A (zh) | 2023-06-01 |
Family
ID=86396581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111129633A TW202320775A (zh) | 2021-11-17 | 2022-08-05 | 含源自大還魂之生物鹼製劑 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240299481A1 (https=) |
| EP (1) | EP4434521A4 (https=) |
| JP (1) | JP7804878B2 (https=) |
| CN (1) | CN118555958A (https=) |
| TW (1) | TW202320775A (https=) |
| WO (1) | WO2023089862A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116253740A (zh) * | 2021-12-10 | 2023-06-13 | 中国科学院上海药物研究所 | 环状双苄基异喹啉类化合物及其制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022553084A1 (en) * | 2020-05-14 | 2024-03-25 | Kowa Co | Novel inhalant |
-
2022
- 2022-07-04 CN CN202280075587.5A patent/CN118555958A/zh active Pending
- 2022-07-04 JP JP2023562123A patent/JP7804878B2/ja active Active
- 2022-07-04 EP EP22895151.3A patent/EP4434521A4/en active Pending
- 2022-07-04 WO PCT/JP2022/026543 patent/WO2023089862A1/ja not_active Ceased
- 2022-08-05 TW TW111129633A patent/TW202320775A/zh unknown
-
2024
- 2024-05-13 US US18/662,946 patent/US20240299481A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240299481A1 (en) | 2024-09-12 |
| JP7804878B2 (ja) | 2026-01-23 |
| EP4434521A1 (en) | 2024-09-25 |
| JPWO2023089862A1 (https=) | 2023-05-25 |
| WO2023089862A1 (ja) | 2023-05-25 |
| EP4434521A4 (en) | 2025-11-05 |
| CN118555958A (zh) | 2024-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Faisal et al. | Alkaloids as potential antivirals. A comprehensive review | |
| CN114191553B (zh) | 抗新型冠状病毒SARS-CoV-2的药物及其应用 | |
| JP5993739B2 (ja) | 神経保護性マンネンタケ組成物およびその使用法 | |
| TWI907588B (zh) | 草藥組成物、其製備方法及將其投藥用於預防或治療病毒感染的方法 | |
| CN111420024B (zh) | 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用 | |
| CN111467363A (zh) | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 | |
| Upadhayay et al. | Frequently used allopathic and traditional medicine for COVID-19 treatment and feasibility of their integration | |
| WO2021203703A1 (zh) | 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用 | |
| CN114306338A (zh) | 双四氢异喹啉类化合物在制备用于预防和/或治疗冠状病毒感染的药物中的应用 | |
| US20240299481A1 (en) | Stephania cepharantha-derived alkaloid-containing preparation | |
| Wei et al. | Antinociceptive activities and mechanism of action of Cepharanthine | |
| WO2021203706A1 (zh) | 膦甲酸钠在制备预防和治疗冠状病毒的药物中的应用 | |
| JPWO2023089862A5 (https=) | ||
| CN102631384B (zh) | 石榴在制备治疗或预防乙型肝炎病毒感染药物中的应用 | |
| CN106038695B (zh) | 鳄梨萃取物、鳄梨醇b及(2r,4r)-1,2,4-三羟基十七碳-16-炔的用途，以及包含鳄梨萃取物的保健食品 | |
| CN113975268B (zh) | 5,6-dehydroeurycomalactone在制备抗登革病毒药物的应用 | |
| Zhang et al. | Delayed administration of Jiuwei Qianghuo Decoction combined with Zhuye Shigao Decoction mitigates the severity of influenza A virus infection by inhibiting cell death and alleviating the subsequent cytokine storm response | |
| AU2017210921B2 (en) | Composition and combined medication method for treating enterovirus infection | |
| CN117159668B (zh) | 化湿败毒颗粒在制备改善地塞米松引起的骨骼肌相关不良反应的药物方面的应用 | |
| TWI827932B (zh) | 創新藥物組合物及其用途 | |
| CN112353809B (zh) | 一种黄芪甲苷类化合物的药物用途 | |
| HK40082238B (zh) | 草药组合物、其制备方法及将其施用以用於预防或治疗病毒感染的方法 | |
| TW202207960A (zh) | 硬毛木防己組成物及其在病毒感染中的用途 | |
| TW202342082A (zh) | 獲得密花豆(ssd)萃取物、其部分及組成物且使用來對抗病毒性疾病之方法 | |
| WO2018107614A1 (zh) | 木犀草素在制备防治登革热病毒感染的药物中的应用 |